Adhesion molecule expression in CD5-negative/CD10-negative chronic B-cell leukemias: Comparison with non-Hodgkin's lymphomas and CD5-positive B-cell chronic lymphocytic leukemia

Abstract

The classification of CD5-negative/CD10-negative chronic B-cell leukemias (CD5−/CD10− CBL) can be problematic. Most of these cases may represent leukemic non-Hodgkin's lymphoma (NHL) other than B-cell chronic lymphocytic leukemia (BCLL); nonetheless, some investigators still advocate the term “CD5-negative BCLL.” Because adhesion molecule (AdMol) expression patterns reflect the biology of lymphoid neoplasms, we studied a series of 106 B-cell lymphoproliferative disorders, including CD5+ BCLL (n = 56), NHL other than BCLL (n = 35), and CD5−/CD10− CBL (excluding hairy cell leukemia and prolymphocytic leukemia) with no prior history of NHL (n = 15) for expression of components of the very late antigen-4 complex (α4/β1 integrin (CD49d/CD29)), components of the mucosal addressin-cell adhesion molecule receptor (α4(CD49d)/β7 integrin), and L-selectin (CD62L). CD62L expression was significantly greater in CD5+ BCLL than in NHL (P <.001). Conversely, CD29, CD49d, and β7-integrin expression were significantly greater in NHL than in CD5+ BCLL (P <.001 for each marker). These differences persisted when only blood and bone marrow samples were analyzed, with the exception of differences in CD62L expression, which approached, but did not reach, statistical significance (P =.08). The group of CD5−/CD10− CBL displayed an AdMol profile similar to NHL and was significantly different than CD5+ BCLL in expression of β7 integrin, CD29, CD49d, and CD62L (P range <.001-.011). In summary, CD5−/CD10− CBL display an AdMol profile resembling NHL and significantly different from CD5+ BCLL, supporting the growing notion that “CD5-negative BCLL” generally represents leukemic NHL rather than a variant of true CD5+ BCLL. HUM PATHOL 32:66-73. Copyright © 2001 by W.B. Saunders Company